{
    "clinical_study": {
        "@rank": "1396", 
        "arm_group": [
            {
                "arm_group_label": "VX-135 low dose in combination with ribavirin", 
                "arm_group_type": "Experimental", 
                "description": "12 weeks of VX-135 in combination with ribavirin"
            }, 
            {
                "arm_group_label": "VX-135 high dose in combination with ribavirin", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of the study is to determine the safety, pharmacokinetics and efficacy of orally\n      administered VX-135 with ribavirin in treatment naive subjects with chronic hepatitis C\n      infection."
        }, 
        "brief_title": "A Phase 2a, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Na\u00efve Subjects With Chronic Hepatitis C", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Hepatitis C", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Up to twenty (20) subjects with CHC GT1 infection will be randomized in a 1:1 ratio (with\n      stratification by IL-28B genotype (CC versus non-CC)) to evaluate VX-135 low dose or high\n      dose both given in combination with RBV for 12 weeks.\n\n      Safety and tolerability will be evaluated on an ongoing basis through assessment of adverse\n      events (AEs), lab evaluations and physical examinations.  Subjects will be monitored from\n      Day 1 through end of follow-up for virologic breakthrough or relapse."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Key Inclusion Criteria:\n\n          -  Subjects (male and female) must be between 18-60 years of age\n\n          -  Subjects must have Chronic Hepatitis C\n\n          -  Subjects must be treatment naive\n\n          -  Subjects must have laboratory values at screening within limits as specified by the\n             protocol\n\n        Key Exclusion Criteria:\n\n          -  Evidence of cirrhosis\n\n          -  Female subjects who are pregnant or nursing or male subjects with a female partner of\n             childbearing potential who is unwilling to adhere to the contraception requirements,\n             is pregnant or nursing, or planning to become pregnant during the study\n\n          -  any other cause of significant liver disease in addition to hepatitis C\n\n          -  Diagnosis of or suspected hepatocellular carcinoma"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01790100", 
            "org_study_id": "ALS-135-101", 
            "secondary_id": "2012-005633-37"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "VX-135 low dose in combination with ribavirin", 
                    "VX-135 high dose in combination with ribavirin"
                ], 
                "description": "12 weeks of VX-135", 
                "intervention_name": "VX-135", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "VX-135 low dose in combination with ribavirin", 
                    "VX-135 high dose in combination with ribavirin"
                ], 
                "description": "12 weeks of ribavirin", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ribavirin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Chisinau", 
                    "country": "Moldova, Republic of"
                }, 
                "name": "Arensia, Republican Clinical Hospital"
            }
        }, 
        "location_countries": {
            "country": "Moldova, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Phase 2a, Partially-Blind, Dose-Ranging Study to Evaluate the Safety, Pharmacokinetics and Efficacy of VX-135 With Ribavirin in Treatment-Na\u00efve Subjects With Chronic Hepatitis C", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "Moldova: Agency of Medicines and Medical Devices", 
                "Moldova: Ministry of Health in the Republic of Moldova"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The safety and tolerability as assessed by evaluating adverse events and laboratory testing.", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "Week 12"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01790100"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The proportion of subjects who have an SVR at 4 weeks after the last planned dose of treatment (SVR4)", 
            "measure": "evidence of HCV RNA viral load reduction", 
            "safety_issue": "No", 
            "time_frame": "16 weeks"
        }, 
        "source": "Alios Biopharma Inc.", 
        "sponsors": {
            "collaborator": {
                "agency": "Vertex Pharmaceuticals Incorporated", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Alios Biopharma Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}